U.S. Prescription Drug Pricing Doesn’t Favor The Patient: Case Of Sub-Optimal Market For Cancer Pharmaceuticals

It’s no surprise people say the healthcare system’s pricing is “rigged.” The drug supply chain is riddled with sub-optimal market features, none of which favor the patient. The blame for high drug prices and out-of-pocket spending goes beyond drug makers, to include PBMs, insurers, and hospitals.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive